Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras-related and estrogen-regulated growth inhibitor-like protein (RERGL)
- Target
- RERGL
- Molecular classification
- Small GTPase, Ras superfamily (Ras small GTPases superfamily)
01
Overview
Ras-related and estrogen-regulated growth inhibitor-like protein (RERGL) is a predicted small GTPase belonging to the Ras superfamily, encoded on human chromosome 12 (gene ID: 79785)[1][5][6]. It binds GDP and GTP, and may possess intrinsic GTPase activity, which implicates it in molecular signal transduction. Structural variation or mutation in RERGL has been associated with genetic susceptibility to colorectal and prostate cancer, and it potentially exerts growth-inhibitory effects under estrogen regulation, similar to its paralog RERG[1][5]. While its detailed biological functions and disease mechanisms are not yet fully understood, RERGL emerges as a candidate gene for further research in cancer predisposition and cell signaling regulation[1][5][6].
- Other names
- RERG likeRERGLRas-related and estrogen-regulated growth inhibitor-like proteinFLJ22655RERG/Ras-like proteinRERG/RAS-like
02
Mechanism of action
Not established for specific drugs; plausible mechanisms would be modulation of GTPase activity or alteration of cell proliferation signaling, inferred from protein family association
03
Biological functions
G protein activity (binds GDP/GTP)GTPase activity (may possess intrinsic GTPase activity)Growth inhibition under estrogen regulationPossible regulation of cell proliferation
04
Disease associations
Cancer (colorectal cancer, prostate cancer)Potential involvement in episodic ataxia, type 4 (genetic association)
05
Safety considerations
No notable safety concerns or therapeutic challenges were found in accessible databases. Further evaluation is needed as its function is not comprehensively characterized
06
Biomarkers
Changes or disruptions (e.g., copy number variation) in RERGL have been preliminarily associated with colorectal cancer risk
Beyond the preview
Go deeper on Ras-related and estrogen-regulated growth inhibitor-like protein (RERGL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ras-related and estrogen-regulated growth inhibitor-like protein (RERGL).